Browsing by Author "Evans, Scott"
Now showing items 1-4 of 4
-
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
Wang, Minggui; Earley, Michelle; Chen, Liang; Hanson, Blake M; Yu, Yunsong; Liu, Zhengyin; Salcedo, Soraya; ... (40 authors) (The Lancet. Infectious diseases, 2021-11-09)<h4>Background</h4>Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across ... -
Clinically Adjudicated Reference Standards for Evaluation of Infectious Diseases Diagnostics.
Patel, Robin; Tsalik, Ephraim L; Evans, Scott; Fowler, Vance G; Doernberg, Sarah B; Antibacterial Resistance Leadership Group (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023-03)Lack of a gold standard can present a challenge for evaluation of diagnostic test accuracy of some infectious diseases tests, particularly when the test's accuracy potentially exceeds that of its predecessors. This approach ... -
MASTERMIND: Bringing Microbial Diagnostics to the Clinic.
Patel, Robin; Tsalik, Ephraim L; Petzold, Elizabeth; Fowler, Vance G; Klausner, Jeffrey D; Evans, Scott; Antibacterial Resistance Leadership Group (ARLG) (Clin Infect Dis, 2017-02-01)New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) ... -
Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.
Williams, Derek J; Creech, C Buddy; Walter, Emmanuel B; Martin, Judith M; Gerber, Jeffrey S; Newland, Jason G; Howard, Lee; ... (21 authors) (JAMA pediatrics, 2022-01-18)<h4>Importance</h4>Childhood community-acquired pneumonia (CAP) is usually treated with 10 days of antibiotics. Shorter courses may be effective with fewer adverse effects and decreased potential for antibiotic ...